Studenovský, M.; Rumlerová, A.; Kovářová, J.; Dvořáková, B.; Sivák, L.; Kostka, L.; Berdár, D.; Etrych, T.; Kovář, M.
HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo. Pharmaceutics 2022, 14, 1201.
https://doi.org/10.3390/pharmaceutics14061201
AMA Style
Studenovský M, Rumlerová A, Kovářová J, Dvořáková B, Sivák L, Kostka L, Berdár D, Etrych T, Kovář M.
HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo. Pharmaceutics. 2022; 14(6):1201.
https://doi.org/10.3390/pharmaceutics14061201
Chicago/Turabian Style
Studenovský, Martin, Anna Rumlerová, Jiřina Kovářová, Barbora Dvořáková, Ladislav Sivák, Libor Kostka, Daniel Berdár, Tomáš Etrych, and Marek Kovář.
2022. "HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo" Pharmaceutics 14, no. 6: 1201.
https://doi.org/10.3390/pharmaceutics14061201
APA Style
Studenovský, M., Rumlerová, A., Kovářová, J., Dvořáková, B., Sivák, L., Kostka, L., Berdár, D., Etrych, T., & Kovář, M.
(2022). HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo. Pharmaceutics, 14(6), 1201.
https://doi.org/10.3390/pharmaceutics14061201